摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-methyl-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid | 91495-97-5

中文名称
——
中文别名
——
英文名称
7-methyl-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid
英文别名
7-Methyl-1,2,3,4-tetrahydro-naphthoesaeure-(1)
7-methyl-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid化学式
CAS
91495-97-5
化学式
C12H14O2
mdl
——
分子量
190.242
InChiKey
DFXDUIHSSBVDIB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    37.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    [(1-ethylpyrazol-4-yl)methyl](4-isopropylphenyl)amine7-methyl-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid 以N-[(1-ethylpyrazol-4-yl)methyl]-N-(4-isopropylphenyl)-7-methyl-1,2,3,4-tetrahydronaphthalene-1-carboxamide (0.41 g) was obtained的产率得到N-[(1-ethylpyrazol-4-yl)methyl]-N-(4-isopropylphenyl)-7-methyl-1,2,3,4-tetrahydronaphthalene-1-carboxamide
    参考文献:
    名称:
    Amide derivatives and medicinal use thereof
    摘要:
    本发明涉及式(1)的酰胺衍生物,具有C5a受体拮抗作用,其中每个符号如规范中所定义。上述酰胺衍生物,其光学活性形式和药学上可接受的盐,作为治疗或预防由C5a引起的炎症引起的疾病或综合征的药剂,具有很大的前景,例如自身免疫性疾病,如风湿病,系统性红斑狼疮等,败血症,成人呼吸窘迫综合症,慢性阻塞性肺疾病,哮喘等过敏性疾病,动脉粥样硬化,心肌梗塞,脑梗塞,牛皮癣,阿尔茨海默病和严重器官损伤(例如肺炎,肾炎,肝炎和胰腺炎等)由缺血再灌注,创伤,烧伤,手术入侵等引起的白细胞激活。此外,它们也可作为治疗或预防通过C5a受体侵入的细菌和病毒引起的传染病的药剂。
    公开号:
    US08198454B2
  • 作为产物:
    描述:
    二氧化碳甲基4-戊基苯甲酸酯 、 C45H38N2O2 、 nickel dichloride 作用下, 以 甲醇N,N-二甲基甲酰胺 为溶剂, 生成 7-methyl-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid 、 6-methyl-1,2,3,4-tetrahydronaphthalene-1-carboxylic acid
    参考文献:
    名称:
    未活化烯烃与 CO2 的催化区域选择性和对映选择性远程加氢羧化
    摘要:
    烯烃与二氧化碳的催化区域和对映选择性加氢羧化是构建对映体富集的 α-手性羧酸的简单策略,但仍然是一个巨大的挑战。在此,我们报告了在 SaBOX/Ni 催化剂的温和条件下,利用丰富且可再生的 CO 2对各种容易获得的未活化烯烃进行高度对映和位点选择性远程加氢羧化的催化例子。这一成功的关键是利用手性 SaBOX 配体,它与镍结合,同时控制链行走和羧化的对映选择性。该方法以高产率和区域选择性和对映选择性直接提供一系列带有各种官能团的不同烷基链取代或苯并稠合的 α-手性羧酸。此外,通过从商业起始材料中简明合成抗血小板聚集药物( R )-吲哚布芬,证明了该方法的合成效用。
    DOI:
    10.1021/jacs.4c05217
点击查看最新优质反应信息

文献信息

  • Novel amide derivatives and medicinal use thereof ugs
    申请人:——
    公开号:US20040138223A1
    公开(公告)日:2004-07-15
    The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action 1 wherein each symbol is as defined in the specification. The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.
    本发明涉及一种式(1)的酰胺衍生物,具有C5a受体拮抗作用,其中每个符号如规范中所定义。上述酰胺衍生物及其光学活性形式和药学上可接受的盐被认为是治疗或预防因C5a引起的炎症引起的疾病或综合症的药物,如自身免疫性疾病,如风湿病,系统性红斑狼疮等,败血症,成人呼吸窘迫综合症,慢性阻塞性肺疾病,哮喘等过敏性疾病,动脉粥样硬化,心脏梗死,脑梗死,牛皮癣,老年痴呆症和严重器官损伤(如肺炎,肾炎,肝炎,胰腺炎等)由于缺血再灌注,创伤,烧伤,手术入侵等引起的白细胞激活。此外,它们对通过C5a受体侵入的细菌和病毒引起的传染病也有用作治疗或预防剂。
  • Novel amide derivatives and medicinal use thereof
    申请人:NAKAMURA Mitsubaru
    公开号:US20100041656A1
    公开(公告)日:2010-02-18
    The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action wherein each symbol is as defined in the specification. The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.
    本发明涉及一种式(1)的酰胺衍生物,具有C5a受体拮抗作用,其中每个符号如规范中所定义。上述酰胺衍生物及其光学活性形式和药学上可接受的盐被认为是治疗或预防由C5a引起的炎症所致疾病或综合症的药物,例如自身免疫性疾病,如风湿病,系统性红斑狼疮等,败血症,成人呼吸窘迫综合症,慢性阻塞性肺疾病,过敏性疾病,如哮喘等,动脉硬化,心脏梗塞,脑梗塞,牛皮癣,阿尔茨海默病和严重器官损伤(例如,肺炎,肾炎,肝炎,胰腺炎等),由缺血再灌注,创伤,烧伤,手术侵袭等引起的白细胞激活所致。此外,它们还可用作通过C5a受体侵入的细菌和病毒引起的传染病的治疗或预防剂。
  • NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF UGS
    申请人:Mitsubishi Pharma Corporation
    公开号:EP1318140A1
    公开(公告)日:2003-06-11
    The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action wherein each symbol is as defined in the specification. The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.
    本发明涉及一种具有 C5a 受体拮抗作用的式 (1) 酰胺衍生物 其中各符号如说明书中所定义。 上述酰胺衍生物、其光学活性形式及其药学上可接受的盐有望用作治疗或预防由 C5a 引起的炎症所导致的疾病或综合征[例如、自身免疫性疾病,如风湿病、系统性红斑狼疮等;败血症;成人呼吸窘迫综合征;慢性阻塞性肺病;过敏性疾病,如哮喘等;动脉粥样硬化;心肌梗塞;脑梗塞;银屑病;老年痴呆症;严重器官损伤(如:肺炎、肾炎、肝硬化等)、由于缺血再灌注、创伤、烧伤、手术侵袭等引起的白细胞活化而导致的严重器官损伤(如肺炎、肾炎、肝炎和胰腺炎等)]。此外,它们还是治疗或预防细菌和病毒通过 C5a 受体入侵引起的感染性疾病的有效药物。
  • NOVEL AMIDE DERIVATIVES AND MEDICINAL USE THEREOF
    申请人:Mitsubishi Tanabe Pharma Corporation
    公开号:EP1318140B9
    公开(公告)日:2012-06-20
  • US7855297B2
    申请人:——
    公开号:US7855297B2
    公开(公告)日:2010-12-21
查看更多